CPHA Canvax

"Rare cases of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart lining) following vaccination with COVID-19 mRNA vaccines have been reported in Canada and internationally. Most cases have occurred in males 12 to 29 years of age after a second dose of an mRNA vaccine. Most cases have been mild and resolved quickly.

Following review of the latest evidence and consultation with Canadian cardiologists, NACI has issued updated guidance on re-vaccination with COVID-19 vaccines for those who experienced myocarditis and/or pericarditis after a previous dose of an mRNA COVID-19 vaccine." - Summary of NACI advice on vaccination with COVID-19 vaccines following myocarditis (with or without pericarditis) 

Rating See Comments Ratings

Category:

Vaccine Safety and Development,Vaccine Safety,Adverse Events Following Immunization (AEFI),Monitoring and Surveillance,Outbreaks and Pandemics,COVID-19,Program Planning and Delivery,Program Delivery and Evaluation,Clinics Vaccine Safety and Development
Vaccine Safety
Adverse Events Following Immunization (AEFI)
Monitoring and Surveillance
Outbreaks and Pandemics
COVID-19
Program Planning and Delivery
Program Delivery and Evaluation
Clinics

0 Comments

Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.

All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.